The successful application of CD19-targeted CAR T cells in refractory cases of autoimmune rheumatic diseases, including SLE, SSc and anti-synthetase syndrome (ASyS), offers a promising innovative treatment modality. The gene discussed is CD19; the disease is systemic sclerosis.